On June 3, BeiGene fell 3.02% in regular trading, trading at HK$163.8/share, with trading volume of approximately HK$291 million.

On the news front, BeiGene recently faced a significant stake reduction by Baker Bros. Advisors LP, a fund affiliated with board directors Julian and Felix Baker, totaling approximately US$190 million. While the fund retains board seats and still holds approximately 8.21% of shares, the sell-off continues to weigh on market sentiment. The reduction was executed at US$260 per ADS when the stock was near its 52-week high, raising concerns over valuation sustainability amid potential competitive threats from Eli Lilly's third-generation BTK inhibitor Pirtobrutinib.

Additionally, the Hong Kong-listed innovative drug sector has been in a correction phase for over eight months since September last year, with the sector benchmark index declining more than 30%. The broader biotech sector weakened today, with Akeso down 4.69%, 3SBio down 3.56%, Innovent Biologics down 2.92%, and Everest Medicines down 3.3%, dragging BeiGene as a heavyweight sector leader.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)